Remotely Monitored ICDs Propel Medtronic’s 6% Market Share Gain
This article was originally published in The Gray Sheet
Executive Summary
Expanding availability and increasing market acceptance of Medtronic's Virtuoso ICD and Concerto cardiac resynchronization therapy product drove a 14% sequential quarterly advance in defibrillator sales, allowing the company to capture market share
You may also be interested in...
Medtronic Loses ICD Market Share, Looks Ahead To U.S. Market Rebound
Medtronic is optimistic about a recovery in the implantable cardioverter defibrillator market, despite lower-than-expected sales in its most recent fiscal quarter, reported Feb. 20
Medtronic Loses ICD Market Share, Looks Ahead To U.S. Market Rebound
Medtronic is optimistic about a recovery in the implantable cardioverter defibrillator market, despite lower-than-expected sales in its most recent fiscal quarter, reported Feb. 20
FDA Investigation Finds No Safety Problems With Medtronic’s Concerto
FDA said it found nothing to warrant concern following a "thorough" investigation of allegations by a former Medtronic employee about the safety of the firm's Concerto cardiac resynchronization/ defibrillator device